Pulmonary Function Decline in Very Early Diagnosis of Systemic Sclerosis: A Retrospective Longitudinal Single-Center Study Eugenio Capparelli, Greta Pellegrino, Eleonora Zaccara, Giorgio Bonardi, Elisabetta Ricchiuti, Daniele Colombo, Maria Sole Chimenti, Paola Faggioli, Antonino Mazzone Acr Open Rheumatology, 2026 Objective The very early diagnosis of systemic sclerosis (SSc; VEDOSS) criteria aim to identify patients at risk of evolving into SSc. The predictive value of diffusing capacity of the lungs for carbon monoxide (DL co) and forced vital capacity (FVC) remains poorly characterized. This study aimed to evaluate whether baseline pulmonary function test (PFT) alterations, especially DL co , predict progression to SSc and to examine longitudinal PFT changes in patients with stable VEDOSS over time. Methods A retrospective longitudinal study was conducted including 73 patients with VEDOSS. Patients were stratified by serologic, capillaroscopic, and clinical features. Annual PFT follow‐up was performed at our center. Progression to SSc was defined according to the 2013 American College of Rheumatology/EULAR criteria. Kaplan–Meier curves were generated to evaluate progression rates according to baseline DL co /single breath (SB)%, using 70% as cutoff, and to evaluate time‐dependent survival of both DL co % and FVC% decline according to the presence or the absence of SSc‐specific antibodies (SSc‐Ab), active‐late nailfold videocapillaroscopic (NVC) patterns, and puffy fingers. A Cox proportional hazards regression model was used to assess the independent association between baseline DL co /SB (%) and progression‐free survival, adjusting for SSc‐Ab+, NVC patterns, and the presence of puffy fingers. Results Over a median follow‐up of five years (maximum 11 years), 12% of patients transitioned to SSc. All progressors were SSc‐Ab+ and had lower baseline DL co /SB% values (68.2% vs 81.2%, P = 0.004). A DL co /SB <70% was strongly associated with increased risk of progression toward SSc over time (7.7 vs 10.2 years, log‐rank = 0.007). In patients with stable VEDOSS, the time‐dependent decline of DL co /SB% was shorter in SSc‐Ab+ group (8 vs 10.4 years, log‐rank = 0.032). FVC% also declined in the cohort without any influence of disease‐specific variables. Cox regression showed that the SSc‐Ab+ and scleroderma NVC pattern were the main contributors to progression toward definite SSc. Conclusion Baseline DL co /SB <70% is a potential marker of disease progression in VEDOSS; however, subtle progressive pulmonary function decline may occur even in stable patients. image
Clinical and serological features of triple autoantibody-negative patients with systemic sclerosis: insights from the multicentric SPRING registry of the Italian Society for Rheumatology Veronica Batani, Ilaria Cavazzana, Martina Orlandi, Rossella De Angelis, Corrado Campochiaro, Enrico De Lorenzis, Gerlando Natalello, Lucrezia Verardi, Gianluigi Bajocchi, Silvia Bellando-Randone, Giovanni Zanframundo, Rosario Foti, Fabio Cacciapaglia, Giovanna Cuomo, Alarico Ariani, Edoardo Rosato, Gemma Lepri, Francesco Girelli, Valeria Riccieri, Elisabetta Zanatta, Francesca Ingegnoli, Maria De Santis, Giuseppe Murdaca, Giuseppina Abignano, Pettiti Giorgio, Alessandra Della Rossa, Maurizio Caminiti, Anna Maria Iuliano, Lorenzo Beretta, Gianluca Bagnato, Ennio Lubrano, Ilenia De Andres, Luca Idolazzi, Cosimo Bruni, Marco Fornaro, Marta Saracco, Cecilia Agnes, Edoardo Cipolletta, Federica Lumetti, Amelia Spinella, Marco De Pinto, Luca Magnani, Veronica Codullo, Elisa Visalli, Carlo Iandoli, Antonietta Gigante, Greta Pellegrino, Erika Pigatto, Maria-Grazia Lazzaroni, Franco Franceschini, Francesca Motta, Antonio Tonutti, Gianna Mennillo, Marco Di Battista, Giuseppa Pagano Mariano, Federica Furini, Licia Vultaggio, Simone Parisi, Clara Lisa Peroni, Gerolamo Bianchi, Enrico Fusaro, Gian Domenico Sebastiani, Marcello Govoni, Salvatore D’Angelo, Franco Cozzi, Serena Guiducci, Andrea Doria, Carlo Salvarani, Florenzo Iannone, Maria Antonietta D’Agostino, Silvia Laura Bosello, Lorenzo Dagna, Dilia Giuggioli, Clodoveo Ferri, Marco Matucci Cerinic, Giacomo De Luca Rmd Open, 2026 Background Antitopoisomerase I (ATA), anticentromere (ACA) and anti-RNA polymerase III (RNAP3) antibodies are included in the 2013 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for systemic sclerosis (SSc). A subset of patients with SSc satisfy criteria but may lack these specific autoantibodies, being classified as ‘triple-negative’. Methods We conducted a retrospective evaluation of triple-negative patients with SSc prevalence and clinical features among the multicentric Systemic sclerosis Progression INvestiGation registry. Results Out of 1480 patients with SSc, 295 (19.9%) were triple-negative, while 1185 (81.1%) had SSc-specific antibodies: ACA (54.3%), ATA (43.6%) and RNAP3 (2.1%). The triple-negative group showed a higher prevalence of myopathy (16.7% vs 10.1%, p=0.003), suggested by higher creatine phosphokinase (CPK) levels (126.2 vs 92.5 U/mL, p=0.002), more frequent CPK increase over 2–3 times (2.4% vs 0.2%, p=0.028). Triple-negative patients also exhibited fewer vascular complications, including digital ulcers (17.3% vs 22.8%, p=0.04) and calcinosis (8.2% vs 12.8%, p=0.027), and a higher prevalence of interstitial lung disease (p<0.001). Consistently, lower diffusing capacity for carbon monoxide (66.4% vs 70.98%, p=0.004) and forced vital capacity (97.01% vs 102.92%, p<0.001) were found in the triple-negative group. Triple-negative patients more frequently received corticosteroids (79.3% vs 67.9%, p=0.003), cyclophosphamide (43.4% vs 26%, p<0.001) and azathioprine (38.5% vs 22.3%, p=0.002), while less frequently received prostanoids (71.6% vs 85.9%, p<0.001), calcium channel blockers (80.1% vs 87.7%, p=0.005) and phosphodiesterase-5 inhibitors (4% vs 20%, p<0.001). Conclusions A higher prevalence of myopathy and interstitial lung disease and a reduced vascular burden were found in the triple-negative patients, suggesting that the non-specific and non-routinely tested autoantibodies may identify an SSc endotype resembling sclero-myositis.
The impact of sex and gender on Fibromyalgia Syndrome: data from the Italian Fibromyalgia Registry Cristina Iannuccelli, Martina Favretti, Giulio Dolcini, Sonia Farah, Marco Di Carlo, Giuseppina Tramontano, Giorgia Ferrari, Fabiola Atzeni, Greta Pellegrino, Piercarlo Sarzi Puttini, Fausto Salaffi, Manuela Di Franco Internal and Emergency Medicine, 2026 Most fibromyalgia (FM) patients are women, with a female-to-male ratio of 3:1. While sex differences in pain perception and description have been reported, the impact of sex and gender on FM severity remains controversial. Additionally, sex-related differential item functioning (DIF) in FM assessment tools has not yet been explored. The primary aim of this study was to analyze sex- and gender-related differences in FM severity using data from a web-based FM registry. The secondary aim was to assess sex-related DIF in three commonly used questionnaires: the Polysymptomatic Distress Scale (PDS), the modified Fibromyalgia Assessment Status (ModFAS), and the revised Fibromyalgia Impact Questionnaire (FIQR). Data from 331 male and 331 female patients, matched for age and body mass index (BMI) and fulfilling ACR 2010/2011 criteria, were retrospectively collected from the Italian Fibromyalgia Registry. Multivariate analyses were conducted on the overall and sex-stratified populations. Sex-related DIF was assessed using a hybrid Ordinal Logistic Regression/Item Response Theory method. Female sex was significantly associated with greater physical impairment, despite no differences in overall disease severity. In stratified analyses, married status influenced disease impact and burden in women, whereas BMI was associated with higher disability in men. Significant sex-related DIF was detected in one item of the Symptom Severity Scale of the PDS. Women with FM experience greater physical impairment than men, despite similar disease severity. Sociodemographic factors influence FM differently across sexes. Despite minor DIF, the three FM-specific questionnaires appear valid for use in both male and female patients.
Source of vaccine information and trust in health care professionals influence vaccine hesitancy in rheumatology patients in Italy Giorgia Carrozzo, Marta Colaneri, Maria Vittoria Cossu, Simone Pagano, Alessandra Mutti, Valeria Colombo, Greta Pellegrino, Donatella Ventura, Giuliana M.C. La Paglia, Alessandro Lucia, Fabiola Atzeni, Piercarlo Sarzi-Puttini, Agostino Riva Clinical and Experimental Rheumatology, 2026 OBJECTIVES: This study aimed to investigate factors related to vaccine hesitancy among patients with autoimmune inflammatory rheumatic diseases (AIIRD) attending two Italian Rheumatology Clinics. METHODS: A survey was distributed to AIIRD patients in two Rheumatology Clinics in Milan and Messina. The survey covered demographic information, medical history, vaccination status, sources of vaccine information and attitudes towards vaccines. A multivariate logistic regression was performed to assess the risk factors associated with not being vaccinated. RESULTS: A total of 371 out of 400 patients responded. Among these, 53.1% reported receiving at least one vaccine among influenza, pneumococcal, meningococcal and zoster, while 18.3% reported no vaccinations and 28.6% were unsure about their vaccination status. Key-factors associated with non-vaccination included reliance on the Internet and social media for vaccine information (p=0.005) and personal knowledge of adverse events (p=0.014). Vaccinated individuals exhibited significantly greater trust in public health agencies (p=0.001), and in vaccine-safety (p=0.004), having an overall more positive attitude towards vaccines (p<0.001). Finally, patients on immunosuppressive therapy were more likely to be vaccinated (OR 2.11, 95% CI 1.05-4.24). CONCLUSIONS: Vaccine hesitancy among AIIRD patients is influenced by several modifiable factors, such as the sources of information they rely on and their level of trust in healthcare professionals. Improving communication between patients and physicians, along with addressing misinformation on digital platforms, could lead to higher vaccine acceptance. Public health initiatives should prioritise targeted interventions that address safety concerns and aim to boost vaccination rates in this high-risk population.
Prevalence, distribution and associations of the scleroderma capillaroscopic patterns: new insights from the Italian SPRING-SIR registry Rossella De Angelis, Clodoveo Ferri, Edoardo Cipolletta, Valeria Riccieri, Marco Di Battista, Gianluigi Bajocchi, Silvia Bellando-Randone, Cosimo Bruni, Martina Orlandi, Giovanni Zanframundo, Roberta Foti, Giovanna Cuomo, Alarico Ariani, Edoardo Rosato, Gemma Lepri, Francesco Girelli, Elisabetta Zanatta, Silvia Laura Bosello, Ilaria Cavazzana, Francesca Ingegnoli, Maria De Santis, Fabio Cacciapaglia, Giuseppe Murdaca, Giuseppina Abignano, Giorgio Pettiti, Alessandra Della Rossa, Maurizio Caminiti, Anna Maria Iuliano, Giovanni Ciano, Lorenzo Beretta, Gianluca Bagnato, Ennio Lubrano, Ilenia De Andres, Luca Idolazzi, Marta Saracco, Cecilia Agnes, Corrado Campochiaro, Marco Fornaro, Federica Lumetti, Amelia Spinella, Emanuele Cocchiara, Giacomo De Luca, Veronica Codullo, Elisa Visalli, Carlo Iandoli, Antonietta Gigante, Greta Pellegrino, Erika Pigatto, Maria Grazia Lazzaroni, Enrico De Lorenzis, Francesca Motta, Antonio Tonutti, Gianna Mennillo, Giuseppa Pagano-Mariano, Federica Furini, Licia Vultaggio, Simone Parisi, Clara Lisa Peroni, Gerolamo Bianchi, Enrico Fusaro, Gian Domenico Sebastiani, Marcello Govoni, Salvatore D’Angelo, Franco Cozzi, Franco Franceschini, Serena Guiducci, Dilia Giuggioli, Lorenzo Dagna, Andrea Doria, Carlo Salvarani, Florenzo Iannone, Marco Matucci-Cerinic, , Amato Giorgio, Benenati Alessia, Calabrese Francesca, Carignola Renato, Dall’Ara Francesca, De Cata Angelo, Doveri Marica, Romeo Nicoletta, Magnani Luca, Sambataro Gianluca, Talotta Rossella, Carlo Alberto Scirè, Gianpiero Landolfi, Davide Rozza, Greta Carrara, Anna Zanetti Rheumatology, 2026 Objectives To assess the relationship between disease duration and the prevalence/distribution of nailfold videocapillaroscopy (NVC) patterns, named according to the current classification as ‘early’, ‘active’ and ‘late’, in a large cohort of systemic sclerosis (SSc) patients. Methods A cross-sectional analysis was conducted on 1689 patients undergoing standardized NVC. Clinical-serological data and treatments were collected. Statistical comparisons and multivariable logistic regression models were applied, including analyses based on disease duration. Results The prevalence of NVC patterns was as follows: ‘early’ 21.6%, ‘active’ 47.4%, ‘late’ 25.7% and normal/non-specific 5.3%. The distribution by disease duration showed that the three main patterns were always present. While the ‘early’ and ‘active’ progressively decreased (from 30.3% and 51.9% in patients with ≤5 yrs, to 14.6% and 43.5% in those &gt;10 yrs, P &lt; 0.01), the ‘late’ pattern increased from 13.2% (≤5 yrs) to 36.0% (&gt;10 yrs) (P &lt; 0.001) and was associated with internal organ involvement, anti-topoisomerase antibodies and more therapies (P &lt; 0.01). Conversely, the ‘early’ and ‘active’ patterns were associated with the limited-cutaneous subset (P &lt; 0.01) and anti-centromere antibodies (P &lt; 0.001). Multivariable analysis confirmed a strong association between the ‘late’ pattern and skin/peripheral vascular involvement. Notably, the presence of the ‘late’ pattern in patients with ≤2 yrs (10.9%) was significantly associated with scleroderma renal crisis (P = 0.012). Conclusion SSc-NVC patterns are not strictly time-dependent and can be observed at any stage of the disease, suggesting that microvascular damage progression is heterogeneous across different disease periods. Therefore, a revised classification of NVC changes considering both disease duration and NVC severity could improve its prognostic accuracy.
Gastrointestinal involvement in very early and established systemic sclerosis: Insights from the SPRING-SIR national Italian registry Francesco Bonomi, Cosimo Bruni, Silvia Peretti, Rossella De Angelis, Gianluigi Bajocchi, Dilia Giuggioli, Martina Orlandi, Giovanni Zanframundo, Rosario Foti, Giovanna Cuomo, Alarico Ariani, Edoardo Rosato, Gemma Lepri, Francesco Girelli, Valeria Riccieri, Elisabetta Zanatta, Silvia Laura Bosello, Ilaria Cavazzana, Francesca Ingegnoli, Maria De Santis, Fabio Cacciapaglia, Giuseppe Murdaca, Giuseppina Abignano, Pettiti Giorgio, Alessandra Della Rossa, Maurizio Caminiti, Anna Maria Iuliano, Giovanni Ciano, Lorenzo Beretta, Gianluca Bagnato, Ennio Lubrano, Ilenia De Andres, Luca Idolazzi, Marta Saracco, Cecilia Agnes, Corrado Campochiaro, Edoardo Cipolletta, Marco Fornaro, Federica Lumetti, Amelia Spinella, Luca Magnani, Giacomo De Luca, Veronica Codullo, Elisa Visalli, Carlo Iandoli, Antonietta Gigante, Greta Pellegrino, Erika Pigatto, Maria Grazia Lazzaroni, Enrico De Lorenzis, Gianna Mennillo, Marco Di Battista, Giuseppa Pagano-Mariano, Federica Furini, Licia Vultaggio, Simone Parisi, Clara Lisa Peroni, Gerolamo Bianchi, Enrico Fusaro, Gian Domenico Sebastiani, Marcello Govoni, Salvatore D’Angelo, Franco Cozzi, Franco Franceschini, Serena Guiducci, Lorenzo Dagna, Andrea Doria, Carlo Salvarani, Maria Antonietta D’Agostino, Florenzo Iannone, Clodoveo Ferri, Marco Matucci-Cerinic, Silvia Bellando Randone, , Francesco Bonomi, Cosimo Bruni, Silvia Peretti, Rossella De Angelis, Gianluigi Bajocchi, Dilia Giuggioli, Martina Orlandi, Giovanni Zanframundo, Rosario Foti, Giovanna Cuomo, Alarico Ariani, Edoardo Rosato, Gemma Lepri, Francesco Girelli, Valeria Riccieri, Elisabetta Zanatta, Silvia Laura Bosello, Ilaria Cavazzana, Francesca Ingegnoli, Maria De Santis, Fabio Cacciapaglia, Giuseppe Murdaca, Giuseppina Abignano, Pettiti Giorgio, Alessandra Della Rossa, Maurizio Caminiti, Anna Maria Iuliano, Giovanni Ciano, Lorenzo Beretta, Gianluca Bagnato, Ennio Lubrano, Ilenia De Andres, Luca Idolazzi, Marta Saracco, Cecilia Agnes, Corrado Campochiaro, Edoardo Cipolletta, Marco Fornaro, Federica Lumetti, Amelia Spinella, Luca Magnani, Giacomo De Luca, Veronica Codullo, Elisa Visalli, Carlo Iandoli, Antonietta Gigante, Greta Pellegrino, Erika Pigatto, Maria Grazia Lazzaroni, Enrico De Lorenzis, Gianna Mennillo, Marco Di Battista, Giuseppa Pagano-Mariano, Federica Furini, Licia Vultaggio, Simone Parisi, Clara Lisa Peroni, Gerolamo Bianchi, Enrico Fusaro, Gian Domenico Sebastiani, Marcello Govoni, Salvatore D’Angelo, Franco Cozzi, Franco Franceschini, Serena Guiducci, Lorenzo Dagna, Andrea Doria, Carlo Salvarani, Maria Antonietta D’Agostino, Florenzo Iannone, Clodoveo Ferri, Marco Matucci-Cerinic, Silvia Bellando Randone Rheumatology, 2026 Objectives To describe the prevalence of gastrointestinal (GI) symptoms in SSc and Very Early Diagnosis of SSc (VEDOSS), identify clinical and serological features associated with GI involvement and explore a cranio-caudal pattern of symptom distribution, using data from the Italian SPRING-SIR registry. Methods This cross-sectional analysis included patients fulfilling 2013 ACR/EULAR SSc or VEDOSS criteria. GI involvement was defined as symptoms in at least one GI tract segment and categorized as upper and lower. Associations between GI involvement and clinical variables were assessed using logistic and ordinal regression models, adjusting for demographics, disease characteristics and autoantibodies. Results Among 1917 SSc patients, 56% had GI symptoms, associated with longer disease duration, dcSSc, interstitial lung disease (ILD), digital ulcers (DU), telangiectasias and tobacco exposure. Extensive GI involvement correlated with more severe disease. Ordinal regression identified female sex, dcSSc, ILD, DU, telangiectasias, tobacco exposure and anti-centromere antibodies as variables significantly associated with more extensive GI involvement. Disease duration did not show a significant association with GI symptom extent. Among 211 VEDOSS patients, 41.2% reported GI symptoms (mostly oesophageal), significantly associated with puffy fingers and dyspnoea. Among VEDOSS, puffy fingers and anti-centromere antibodies were independent predictors of presence of oesophageal symptoms. Conclusion GI involvement in SSc is linked to more severe disease and longer disease duration. Disease duration resulted linked to the presence of GI symptoms rather than extent of GI involvement. Puffy fingers and anti-centromere antibodies may associate with presence of early oesophageal symptoms in VEDOSS.
Age and onset timing of Raynaud’s phenomenon and first non-Raynaud symptom as prognostic factors in systemic sclerosis: a retrospective analysis from the Italian national multicenter Systemic Sclerosis Progression INvestiGation registry of the Italian Society for Rheumatology (SPRING-SIR) Silvia Peretti, Cosimo Bruni, Francesco Bonomi, Rossella De Angelis, Gianluigi Bajocchi, Dilia Giuggioli, Martina Orlandi, Giovanni Zanframundo, Roberta Foti, Elisa Visalli, Giovanna Cuomo, Alarico Ariani, Edoardo Rosato, Gemma Lepri, Francesco Girelli, Valeria Riccieri, Elisabetta Zanatta, Silvia Laura Bosello, Ilaria Cavazzana, Francesca Ingegnoli, Maria De Santis, Fabio Cacciapaglia, Giuseppe Murdaca, Giuseppina Abignano, Giorgio Pettiti, Alessandra Della Rossa, Maurizio Caminiti, Annamaria Iuliano, Giovanni Ciano, Lorenzo Beretta, Gianluca Bagnato, Ennio Lubrano, Ilenia De Andres, Luca Idolazzi, Marta Saracco, Cecilia Agnes, Corrado Campochiaro, Giacomo De Luca, Edoardo Cipolletta, Marco Fornaro, Federica Lumetti, Amelia Spinella, Luca Magnani, Veronica Codullo, Carlo Iandoli, Antonietta Gigante, Greta Pellegrino, Erika Pigatto, Maria Grazia Lazzaroni, Enrico De Lorenzis, Gianna Angela Mennillo, Marco Di Battista, Giuseppa Pagano Mariano, Federica Furini, Licia Vultaggio, Simone Parisi, Clara Lisa Peroni, Gerolamo Bianchi, Enrico Fusaro, Gian Domenico Sebastiani, Marcello Govoni, Salvatore D’Angelo, Franco Cozzi, Franco Franceschini, Serena Guiducci, Lorenzo Dagna, Andrea Doria, Carlo Salvarani, Maria Antonietta D’Agostino, Florenzo Iannone, Marco Matucci-Cerinic, Clodoveo Ferri, Silvia Bellando Randone Therapeutic Advances in Musculoskeletal Disease, 2026 Background: The sequence and temporal relationship between Raynaud’s phenomenon (RP) and the first non-Raynaud’s sign/symptom (NRP) in systemic sclerosis (SSc) have been partially investigated. Objectives: To evaluate whether the mode and ages of clinical onset are associated with disease endotype and survival in SSc. Design: We included SSc patients from the Systemic sclerosis Progression INvestiGation registry of the Italian Society of Rheumatology (SPRING-SIR) registry in a cohort study, with post hoc cross-sectional and longitudinal analysis. Methods: Patients were grouped based on age-RP and age-NRP quartiles. Additionally, categories were defined based on mode of onset: RP group—RP onset at least 1 year before NRP; Simultaneous group—RP onset within the same year of NRP; NRP group—RP onset after at least 1 year after NRP. Comparisons were made using Chi-square and ANOVA tests. Logistic, linear, and multinomial regression models were applied to assess associations, while Kaplan–Meier curves and Cox regression were used to assess mortality. Results: A total of 1748 patients were eligible: 682 (39.0%) in the RP group, 1026 (58.8%) in the simultaneous group, and 39 (2.2%) in the NRP group. A higher prevalence of anti-centromere antibodies was found In the RP group, while the simultaneous group had more diffuse cutaneous SSc (dcSSc), anti-topoisomerase-I antibodies, and higher Rodnan’s skin score (mRSS). The NRP group presented higher prevalence of pulmonary arterial hypertension. On logistic regression, the simultaneous group was associated with a higher prevalence of dcSSc compared to the RP group (odds ratio, 1.491, 95% confidence interval (CI): 1.032–2.154). Younger age at RP onset was associated with lower systolic pulmonary artery pressure and mRSS. In 943 patients with available follow-up (median 24 months), the simultaneous group had higher mortality compared to the RP group (hazard ratio, 1.975, 95% CI: 1.002–3.893). Conclusion: The timing of RP and NRP onset may help define SSc endotype and survival. Patients with simultaneous RP-NRP onset have more severe disease features and higher mortality risk, emphasizing the relevance of onset timing in disease stratification.
Mycophenolate Mofetil Treatment Reduces the Risk of Treatment Escalation Due to Vascular Complications in Limited Cutaneous Systemic Sclerosis: Emulation of a Target Trial From the Italian Rheumatology Society SPRING Registry Enrico De Lorenzis, Gerlando Natalello, Rossella De Angelis, Lucrezia Verardi, Dilia Giuggioli, Gianluigi Bajocchi, Lorenzo Dagna, Silvia Bellando‐Randone, Giovanni Zanframundo, Rosario Foti, Fabio Cacciapaglia, Giovanna Cuomo, Alarico Ariani, Edoardo Rosato, Gemma Lepri, Francesco Girelli, Valeria Riccieri, Elisabetta Zanatta, Ilaria Cavazzana, Francesca Ingegnoli, Maria De Santis, Giuseppe Murdaca, Giuseppina Abignano, Giorgio Pettiti, Alessandra Della Rossa, Maurizio Caminiti, Annamaria Iuliano, Giovanni Ciano, Lorenzo Beretta, Gianluca Bagnato, Ennio Lubrano, Maria Ilenia De Andres, Alessandro Giollo, Cosimo Bruni, Martina Orlandi, Marco Fornaro, Marta Saracco, Cecilia Agnes, Pier Giacomo Cerasuolo, Gabriella Alonzi, Edoardo Cipolletta, Federica Lumetti, Amelia Spinella, Luca Magnani, Corrado Campochiaro, Giacomo De Luca, Veronica Codullo, Elisa Visalli, Carlo Iandoli, Antonietta Gigante, Greta Pellegrino, Erika Pigatto, Maria‐Grazia Lazzaroni, Franco Franceschini, Elena Generali, Gianna Mennillo, Simone Barsotti, Giuseppa Pagano Mariano, Federica Furini, Licia Vultaggio, Simone Parisi, Clara Lisa Peroni, Gerolamo Bianchi, Enrico Fusaro, Gian Domenico Sebastiani, Marcello Govoni, Salvatore D'Angelo, Franco Cozzi, Fabrizio Conti, Serena Guiducci, Andrea Doria, Carlo Salvarani, Florenzo Iannone, Maria Antonietta D'Agostino, Clodoveo Ferri, Marco Matucci Cerinic, Silvia Laura Bosello, and Arthritis Care and Research, 2026 Objective Mycophenolate mofetil (MMF) use in limited cutaneous systemic sclerosis (lcSSc) is relatively uncommon because of the lower fibrotic burden and the predominance of vascular complications. In vitro observations and clinical data from transplanted patients suggest a protective effect of MMF on endothelial function. Our aim was to evaluate the reasons for prescribing MMF treatment in patients with lcSSc and its impact on the need for escalation of vascular complication–related treatments during follow‐up. Methods Patients with lcSSc enrolled in the Italian Systemic Sclerosis Progression Investigation registry were retrospectively evaluated. All patients treated with MMF were matched to patients not treated with MMF, which was based on a roll‐entry time‐dependent propensity score built on demographics, clinical features, and baseline treatment. The escalation of vasoactive or vasodilator treatment up to 60 months was defined as the introduction of iloprost, endothelin receptor antagonists, or phosphodiesterase‐5 inhibitors on top of the ongoing treatment, because of uncontrolled or newly diagnosed vascular complications. A hazards Cox model was also adopted to quantify the association of MMF treatment with treatment escalation. Results A total of 1,435 patients with lcSSc were evaluated, of whom 152 were prescribed MMF (17.1% male; mean age at lcSSc onset 48.7 ± 13.9 years, 54.6% anti‐Scl70 positive). The prescription of MMF was more common in men and in anti‐Scl70 positive, anticentromere negative patients with interstitial lung disease, myositis, and without a history of digital ulcers. After matching 107 patients with MMF‐untreated controls, the overall incidence of vasoactive/vasodilator treatment escalation events related to digital ulcers over a median follow‐up of 40.5 months (interquartile range 23.3–60.0) was 0.3 per 100 patient‐years in the MMF‐treated group and 5.4 per 100 patient‐years in the matched control group, with a significant difference in treatment escalation‐free survival between the two groups (hazard ratio 0.05, 95% confidence interval 0.01–0.38; P value = 0.004). Conclusion In patients with lcSSc, the introduction of MMF has reduced the need for escalation of vasoactive or vasodilator treatment, suggesting that it may also help to prevent vascular complications, which frequently affect patients with lcSSc.
Elderly-onset systemic sclerosis defines a distinct clinical subset: analysis from the SPRING registry of the Italian Society for Rheumatology Antonio Tonutti, Francesca Motta, Gianluigi Bajocchi, Silvia Bellando-Randone, Cosimo Bruni, Martina Orlandi, Giovanni Zanframundo, Roberta Foti, Giovanna Cuomo, Alarico Ariani, Edoardo Rosato, Gemma Lepri, Francesco Girelli, Elisabetta Zanatta, Silvia Laura Bosello, Ilaria Cavazzana, Francesca Ingegnoli, Fabio Cacciapaglia, Giuseppe Murdaca, Giuseppina Abignano, Giorgio Pettiti, Alessandra Della Rossa, Maurizio Caminiti, Annamaria Iuliano, Giovanni Ciano, Lorenzo Beretta, Gianluca Bagnato, Ennio Lubrano, Ilenia De Andres, Luca Idolazzi, Marta Saracco, Cecilia Agnes, Corrado Campochiaro, Mariangela Nivuori, Edoardo Cipolletta, Federica Lumetti, Amelia Spinella, Emanuele Cocchiara, Giacomo De Luca, Veronica Codullo, Elisa Visalli, Carlo Iandoli, Antonietta Gigante, Greta Pellegrino, Erika Pigatto, Maria Grazia Lazzaroni, Enrico De Lorenzis, Gianna Mennillo, Marco Di Battista, Giuseppa Pagano-Mariano, Federica Furini, Licia Vultaggio, Simone Parisi, Maria Chiara Ditto, Gerolamo Bianchi, Enrico Fusaro, Gian Domenico Sebastiani, Marcello Govoni, Salvatore D'Angelo, Franco Cozzi, Franco Franceschini, Serena Guiducci, Lorenzo Dagna, Andrea Doria, Dilia Giuggioli, Valeria Riccieri, Carlo Salvarani, Florenzo Iannone, Clodoveo Ferri, Marco Matucci-Cerinic, Maria De Santis, Rossella De Angelis Journal of Autoimmunity, 2025 OBJECTIVE: Elderly-onset systemic sclerosis (SSc) is relatively uncommon, and its clinical phenotype and prognostic implications remain poorly characterized, with conflicting evidence regarding disease course and outcomes. METHODS: Within the Italian SPRING (Systemic Sclerosis PRogression INvestiGation) registry, we compared demographic and clinical characteristics of patients with elderly-onset SSc (≥70 years at the time of the first non-Raynaud's manifestation) to those with younger onset. Cross-sectional analyses, multivariable logistic regression, and unsupervised cluster analysis were conducted to identify features associated with elderly-onset SSc. Longitudinal analysis was performed to assess mortality risk within SSc patients and compared to the general Italian population. RESULTS: Elderly-onset accounted for 8.5 % (160/1893) SSc cases in SPRING. These patients exhibited fewer peripheral vascular complications (digital ulcers: 13 % vs. 23 %; p = 0.016), higher prevalence of anticentromere antibodies (60 % vs. 39 %; p = 0.007), a lower prevalence and likelihood of diffuse skin subset (OR 0.40; 95 % CI 0.19-0.83) but an increased risk of pulmonary arterial hypertension confirmed on right-heart catheterization (OR 14.1; 95 % CI 3.68-54.5) at multivariate analysis. As expected, patients with elderly onset SSc had an increased risk of death compared to younger-onset individuals. Compared with the age-, sex-, and calendar year-matched general Italian population, patients with SSc showed a fivefold increased mortality, with a trend toward a higher risk in young-onset (SMR 6.3; 95 %CI 4.1-9.1) compared with elderly-onset (SMR 4.5; 95 %CI 2.4-7.7) cases. CONCLUSIONS: Elderly-onset identifies a distinct clinical subset of SSc, mainly characterized by mild cutaneous and peripheral vascular involvement, but showing a greater burden of pulmonary vascular disease and increased mortality compared to the age-matched general population.
First-line diagnostic tests to intercept primary heart involvement in systemic sclerosis: Clinical associations from the SPRING-SIR registry Antonio Tonutti, Francesca Motta, Rossella De Angelis, Edoardo Cipolletta, Clodoveo Ferri, Gianluigi Bajocchi, Silvia Bellando‐Randone, Cosimo Bruni, Martina Orlandi, Giovanni Zanframundo, Rosario Foti, Giovanna Cuomo, Alarico Ariani, Edoardo Rosato, Gemma Lepri, Francesco Girelli, Elisabetta Zanatta, Silvia Laura Bosello, Ilaria Cavazzana, Francesca Ingegnoli, Fabio Cacciapaglia, Giuseppe Murdaca, Giuseppina Abignano, Giorgio Pettiti, Alessandra Della Rossa, Maurizio Caminiti, Anna Maria Iuliano, Giovanni Ciano, Lorenzo Beretta, Gianluca Bagnato, Ennio Lubrano, Ilenia De Andres, Luca Idolazzi, Marta Saracco, Cecilia Agnes, Corrado Campochiaro, Marco Fornaro, Federica Lumetti, Amelia Spinella, Luca Magnani, Giacomo De Luca, Veronica Codullo, Elisa Visalli, Carlo Iandoli, Antonietta Gigante, Greta Pellegrino, Erika Pigatto, Maria Grazia Lazzaroni, Enrico De Lorenzis, Gianna Mennillo, Marco Di Battista, Giuseppa Pagano‐Mariano, Federica Furini, Licia Vultaggio, Simone Parisi, Clara Lisa Peroni, Gerolamo Bianchi, Enrico Fusaro, Gian Domenico Sebastiani, Marcello Govoni, Salvatore D'Angelo, Franco Cozzi, Franco Franceschini, Serena Guiducci, Lorenzo Dagna, Andrea Doria, Dilia Giuggioli, Valeria Riccieri, Carlo Salvarani, Florenzo Iannone, Marco Matucci‐Cerinic, Carlo Selmi, Maria De Santis, and European Journal of Clinical Investigation, 2025 IntroductionPrimary heart involvement (pHI) is an overlooked and poorly characterised complication of systemic sclerosis (SSc), associated with the risk of heart failure, arrhythmia and death. Despite consensus definition by the World Scleroderma Foundation/Heart Failure Association (WSF/HFA), diagnostic criteria and risk factors remain poorly elucidated.MethodsOut of 1922 patients in the Italian national SPRING registry, we excluded those with potentially confounding conditions according to WSF/HFA, and those with incomplete ECG or echocardiographic assessment, resulting in 600 subjects with clearly defined parameters to intercept SSc‐pHI. Cross‐sectional and longitudinal analyses were performed to identify factors associated with pHI.ResultsECG and/or echocardiographic signs of SSc‐pHI were identified in 25% of patients at enrollment and were associated with older age (OR 1.04; 95% CI 1.02–1.06), diffuse cutaneous SSc (OR 1.85; 95% CI 1.05–3.26) and intestinal symptoms (OR 1.79; 95% CI 1.03–3.08). Diastolic dysfunction (62%) and conduction disturbances (34%) were the most frequent phenotypes, while diffuse hypokinesia with reduced ejection fraction was the least common (3%). During follow‐up, new‐onset signs of pHI were observed in an additional 25% of patients, particularly in those with skeletal muscle involvement (HR 2.83; 95% CI 1.01–7.73).ConclusionspHI is a severe complication potentially affecting one‐quarter of patients with SSc. Early detection is crucial, particularly in those with diffuse skin fibrosis, muscular involvement and intestinal manifestations.
Prevalence and clinical relevance of digital ulcers in systemic sclerosis patients from the real-life: the experience of the SPRING Registry of the Italian Society for Rheumatology Martina Orlandi, Giacomo De Luca, Clodoveo Ferri, Amelia Spinella, Federica Lumetti, Riccardo Cuoghi Costantini, Rossella De Angelis, Valeria Riccieri, Silvia Laura Bosello, Fabio Cacciapaglia, Veronica Codullo, Gianluigi Bajocchi, Corrado Campochiaro, Giovanni Zanframundo, Rosario Foti, Giovanna Cuomo, Alarico Ariani, Edoardo Rosato, Francesco Girelli, Elisabetta Zanatta, Ilaria Cavazzana, Francesca Ingegnoli, Maria De Santis, Giuseppe Murdaca, Giuseppina Abignano, Pettiti Giorgio, Alessandra Della Rossa, Maurizio Caminiti, Anna Maria Iuliano, Giovanni Ciano, Lorenzo Beretta, Gianluca Bagnato, Ennio Lubrano, Ilenia De Andres, Alessandro Giollo, Marta Saracco, Cecilia Agnes, Edoardo Cipolletta, Luca Magnani, Elisa Visalli, Carlo Iandoli, Antonietta Gigante, Greta Pellegrino, Erika Pigatto, Maria Grazia Lazzaroni, Franco Franceschini, Elena Generali, Gianna Mennillo, Simone Barsotti, Giuseppa Pagano Mariano, Federica Furini, Licia Vultaggio, Simone Parisi, Clara Lisa Peroni, Gerolamo Bianchi, Enrico Fusaro, Gian Domenico Sebastiani, Marcello Govoni, Salvatore D’Angelo, Franco Cozzi, Serena Guiducci, Andrea Doria, Carlo Salvarani, Florenzo Iannone, Lorenzo Dagna, Marco Matucci-Cerinic, Silvia Bellando-Randone, Dilia Giuggioli, , Giorgio Amato, Alessia Benenati, Francesca Calabrese, Renato Carignola, Francesca Dall’Ara, Angelo De Cata, Marica Doveri, Nicoletta Romeo, Gianluca Sambataro, Rossella Talotta, Carlo Alberto Scirè, Gianpiero Landolfi, Davide Rozza, Greta Carrara, Anna Zanetti Clinical Rheumatology, 2025
Vagal nerve stimulation and fibromyalgia: an additional therapeutic option Giulio Dolcini, Martina Favretti, Daniele Franculli, Giorgia Buoncuore, Greta Pellegrino, Marco Di Carlo, Piercarlo Sarzi Puttini, Fabrizio Conti, Cristina Iannuccelli, Manuela Di Franco Clinical and Experimental Rheumatology, 2025
Fibromyalgia: one year in review 2025 Cristina Iannuccelli, Martina Favretti, Giulio Dolcini, Marco Di Carlo, Greta Pellegrino, Laura Bazzichi, Fabiola Atzeni, Daniela Lucini, Giustino Varassi, Matteo Luigi Giuseppe Leoni, Diego Maria Michele Fornasari, Fabrizio Conti, Fausto Salaffi, Piercarlo Sarzi Puttini, Manuela Di Franco Clinical and Experimental Rheumatology, 2025
Long-term retention rate, adverse event temporal patterns and rescue treatment strategies of mycophenolate mofetil in systemic sclerosis: insights from real-life Enrico De Lorenzis, Gerlando Natalello, Greta Pellegrino, Lucrezia Verardi, Veronica Batani, Gemma Lepri, Stefano Stano, Giuseppe Armentano, Marco De Pinto, Francesca Motta, Stefano Di Donato, Vishal Kakkar, Silvia Fiore, Ilaria Bisconti, Corrado Campochiaro, Laura Cometi, Antonio Tonutti, Amalia Spinella, Simona Truglia, Silvia Cavalli, Maria De Santis, Dilia Giuggioli, Nicoletta Del Papa, Serena Guiducci, Fabio Cacciapaglia, Giacomo De Luca, Fiorenzo Iannone, Valeria Ricceri, Marco Matucci Cerinic, Maria Antonietta D’Agostino, Francesco Del Galdo, Silvia Laura Bosello Rheumatology, 2025
Pulmonary Arterial Hypertension Incidence in Patients With Systemic Sclerosis Treated With Bosentan for Digital Ulcers: Evidence From the SPRING-SIR Registry Fabio Cacciapaglia, Rossella De Angelis, Clodoveo Ferri, Gianluigi Bajocchi, Silvia Bellando-Randone, Cosimo Bruni, Martina Orlandi, Marco Fornaro, Edoardo Cipolletta, Giovanni Zanframundo, Roberta Foti, Giovanna Cuomo, Alarico Ariani, Edoardo Rosato, Gemma Lepri, Francesco Girelli, Elisabetta Zanatta, Silvia L. Bosello, Ilaria Cavazzana, Francesca Ingegnoli, Maria De Santis, Giuseppe Murdaca, Giuseppina Abignano, Pettiti Giorgio, Alessandra Della Rossa, Maurizio Caminiti, Annamaria Iuliano, Giovanni Ciano, Lorenzo Beretta, Gianluca Bagnato, Ennio Lubrano, Ilenia De Andres, Alessandro Giollo, Marta Saracco, Cecilia Agnes, Corrado Campochiaro, Federica Lumetti, Amelia Spinella, Luca Magnani, Giacomo De Luca, Veronica Codullo, Elisa Visalli, Carlo Iandoli, Antonietta Gigante, Greta Pellegrino, Franco Cozzi, Maria G. Lazzaroni, Elena Generali, Gianna Mennillo, Simone Barsotti, Giuseppa Pagano-Mariano, Federica Furini, Licia Vultaggio, Simone Parisi, Clara Lisa Peroni, Gerolamo Bianchi, Enrico Fusaro, Gian D. Sebastiani, Marcello Govoni, Salvatore D'Angelo, Erika Pigatto, Franco Franceschini, Serena Guiducci, Lorenzo Dagna, Andrea Doria, Dilia Giuggioli, Valeria Riccieri, Carlo Salvarani, Marco Matucci-Cerinic, Florenzo Iannone Journal of Rheumatology, 2025
Menopause in systemic sclerosis: the impact on clinical presentation in a multicenter cross-sectional analysis from the National Registry of the Italian Society for Rheumatology (SPRING-SIR) Martina Orlandi, Dilia Giuggioli, Clodoveo Ferri, Rossella De Angelis, Valeria Riccieri, Fabio Cacciapaglia, Silvia Laura Bosello, Veronica Codullo, Gianluigi Bajocchi, Lorenzo Dagna, Corrado Campochiaro, Giacomo De Luca, Giovanni Zanframundo, Rosario Foti, Giovanna Cuomo, Alarico Ariani, Edoardo Rosato, Francesco Girelli, Elisabetta Zanatta, Ilaria Cavazzana, Francesca Ingegnoli, Maria De Santis, Giuseppe Murdaca, Giuseppina Abignano, Giorgio Petitti, Alessandra Della Rossa, Maurizio Caminiti, Anna Maria Iuliano, Giovanni Ciano, Lorenzo Beretta, Gianluca Bagnato, Ennio Lubrano, Ilenia De Andres, Alessandro Giollo, Marta Saracco, Cecilia Agnes, Edoardo Cipolletta, Federica Lumetti, Amelia Spinella, Luca Magnani, Elisa Visalli, Carlo Iandoli, Antonietta Gigante, Greta Pellegrino, Erika Pigatto, Maria Grazia Lazzaroni, Franco Franceschini, Elena Generali, Gianna Mennillo, Simone Barsotti, Giuseppa Pagano Mariano, Federica Furini, Licia Vultaggio, Simone Parisi, Clara Lisa Peroni, Gerolamo Bianchi, Enrico Fusaro, Gian Domenico Sebastiani, Marcello Govoni, Salvatore D’Angelo, Franco Cozzi, Andrea Doria, Carlo Salvarani, Florenzo Iannone, Serena Guiducci, Silvia Bellando-Randone, Marco Matucci-Cerinic, Cosimo Bruni Therapeutic Advances in Musculoskeletal Disease, 2025
Pharmacological Treatment of Fibromyalgia Syndrome: A Practice-Based Review Valeria Giorgi, Piercarlo Sarzi-Puttini, Greta Pellegrino, Silvia Sirotti, Fabiola Atzeni, Alessandra Alciati, Riccardo Torta, Giustino Varrassi, Diego Fornasari, Stefano Coaccioli, Sara Francesca Bongiovanni Current Pain and Headache Reports, 2024
Fibromyalgia: one year in review 2024 Marco Di Carlo, Benedetta Bianchi, Fausto Salaffi, Greta Pellegrino, Cristina Iannuccelli, Valeria Giorgi, Piercarlo Sarzi-Puttini Clinical and Experimental Rheumatology, 2024
Practice pattern for the use of intravenous iloprost for the treatment of peripheral vasculopathy in systemic sclerosis: A case–control study from the Italian national multicenter “SPRING” (Systemic Sclerosis Progression InvestiGation) Registry Valeria Riccieri, Greta Pellegrino, Edoardo Cipolletta, Dilia Giuggioli, Gianluigi Bajocchi, Silvia Bellando-Randone, Lorenzo Dagna, Giovanni Zanframundo, Rosario Foti, Fabio Cacciapaglia, Giovanna Cuomo, Alarico Ariani, Edoardo Rosato, Gemma Lepri, Francesco Girelli, Elisabetta Zanatta, Silvia Laura Bosello, Ilaria Cavazzana, Francesca Ingegnoli, Maria De Santis, Giuseppe Murdaca, Giuseppina Abignano, Nicoletta Romeo, Alessandra Della Rossa, Maurizio Caminiti, Annamaria Iuliano, Giovanni Ciano, Lorenzo Beretta, Gianluca Bagnato, Ennio Lubrano, Ilenia De Andres, Alessandro Giollo, Marta Saracco, Cecilia Agnes, Federica Lumetti, Amelia Spinella, Luca Magnani, Corrado Campochiaro, Giacomo De Luca, Veronica Codullo, Elisa Visalli, Claudio Di Vico, Antonietta Gigante, Francesca Saccon, Maria Grazia Lazzaroni, Franco Franceschini, Elena Generali, Gianna Mennillo, Simone Barsotti, Giuseppa Pagano Mariano, Francesca Calabrese, Federica Furini, Licia Vultaggio, Simone Parisi, Clara Lisa Peroni, Gerolamo Bianchi, Fabrizio Conti, Franco Cozzi, Salvatore D’Angelo, Andrea Doria, Enrico Fusaro, Marcello Govoni, Serena Guiducci, Florenzo Iannone, Carlo Salvarani, Gian Domenico Sebastiani, Clodoveo Ferri, Marco Matucci-Cerinic, Rossella De Angelis Journal of Scleroderma and Related Disorders, 2024
Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase Clodoveo Ferri, Vincenzo Raimondo, Dilia Giuggioli, Laura Gragnani, Serena Lorini, Lorenzo Dagna, Silvia Laura Bosello, Rosario Foti, Valeria Riccieri, Serena Guiducci, Giovanna Cuomo, Antonio Tavoni, Rossella De Angelis, Fabio Cacciapaglia, Elisabetta Zanatta, Franco Cozzi, Giuseppe Murdaca, Ilaria Cavazzana, Nicoletta Romeo, Veronica Codullo, Roberta Pellegrini, Giuseppe Varcasia, Maria De Santis, Carlo Selmi, Giuseppina Abignano, Maurizio Caminiti, Massimo L'Andolina, Domenico Olivo, Ennio Lubrano, Amelia Spinella, Federica Lumetti, Giacomo De Luca, Piero Ruscitti, Teresa Urraro, Marcella Visentini, Silvia Bellando-Randone, Elisa Visalli, Davide Testa, Gabriella Sciascia, Francesco Masini, Greta Pellegrino, Francesca Saccon, Eugenia Balestri, Giusy Elia, Silvia Martina Ferrari, Antonio Tonutti, Francesca Dall’Ara, Giuseppa Pagano Mariano, Giorgio Pettiti, Giovanni Zanframundo, Raffaele Brittelli, Vincenzo Aiello, Ylenia Dal Bosco, Roberta Foti, Ilenia Di Cola, Daniela Scorpiniti, Enrico Fusaro, Tommaso Ferrari, Pietro Gigliotti, Corrado Campochiaro, Francesca Francioso, Carlo Iandoli, Virginia Caira, Anna Linda Zignego, Salvatore D'Angelo, Franco Franceschini, Marco Matucci-Cerinic, Roberto Giacomelli, Andrea Doria, Stefano Angelo Santini, Poupak Fallahi, Florenzo Iannone, Alessandro Antonelli Journal of Translational Autoimmunity, 2023
Fibromyalgia: one year in review 2023 Valeria Giorgi, Laura Bazzichi, Alberto Batticciotto, Greta Pellegrino, Manuela Di Franco, Silvia Sirotti, Fabiola Atzeni, Alessandra Alciati, Fausto Salaffi, Piercarlo Sarzi Puttini Clinical and Experimental Rheumatology, 2023
Systemic sclerosis sine scleroderma: clinical and serological features and relationship with other cutaneous subsets in a large series of patients from the national registry 'SPRING' of the Italian Society for Rheumatology Rossella De Angelis, Clodoveo Ferri, Dilia Giuggioli, Gianluigi Bajocchi, Lorenzo Dagna, Silvia Bellando-Randone, Giovanni Zanframundo, Rosario Foti, Fabio Cacciapaglia, Giovanna Cuomo, Alarico Ariani, Edoardo Rosato, Gemma Lepri, Francesco Girelli, Valeria Riccieri, Elisabetta Zanatta, Silvia Laura Bosello, Ilaria Cavazzana, Francesca Ingegnoli, Maria De Santis, Giuseppe Murdaca, Giuseppina Abignano, Nicoletta Romeo, Alessandra Della Rossa, Maurizio Caminiti, Anna Maria Iuliano, Giovanni Ciano, Lorenzo Beretta, Gianluca Bagnato, Ennio Lubrano, Ilenia De Andres, Alessandro Giollo, Marta Saracco, Cecilia Agnes, Edoardo Cipolletta, Federica Lumetti, Amelia Spinella, Luca Magnani, Corrado Campochiaro, Giacomo De Luca, Veronica Codullo, Elisa Visalli, Claudio Di Vico, Antonietta Gigante, Greta Pellegrino, Erika Pigatto, Maria-Grazia Lazzaroni, Franco Franceschini, Elena Generali, Gianna Mennillo, Simone Barsotti, Giuseppa Pagano Mariano, Federica Furini, Licia Vultaggio, Simone Parisi, Clara Lisa Peroni, Davide Rozza, Anna Zanetti, Greta Carrara, Gianpiero Landolfi, Carlo Alberto Scirè, Gerolamo Bianchi, Enrico Fusaro, Gian Domenico Sebastiani, Marcello Govoni, Salvatore D'Angelo, Franco Cozzi, Serena Guiducci, Andrea Doria, Carlo Salvarani, Florenzo Iannone, Marco Matucci-Cerinic Rmd Open, 2023
Geographical heterogeneity of clinical and serological phenotypes of systemic sclerosis observed at tertiary referral centres. The experience of the Italian SIR-SPRING registry and review of the world literature Clodoveo Ferri, Rossella De Angelis, Dilia Giuggioli, Gianluigi Bajocchi, Lorenzo Dagna, Giovanni Zanframundo, Rosario Foti, Fabio Cacciapaglia, Giovanna Cuomo, Alarico Ariani, Edoardo Rosato, Serena Guiducci, Francesco Girelli, Valeria Riccieri, Elisabetta Zanatta, Silvia Bosello, Ilaria Cavazzana, Francesca Ingegnoli, Maria De Santis, Giuseppe Murdaca, Giuseppina Abignano, Nicoletta Romeo, Alessandra Della Rossa, Maurizio Caminiti, Annamaria Iuliano, Giovanni Ciano, Lorenzo Beretta, Gianluca Bagnato, Ennio Lubrano, Ilenia De Andres, Alessandro Giollo, Marta Saracco, Cecilia Agnes, Federica Lumetti, Amelia Spinella, Luca Magnani, Corrado Campochiaro, Giacomo De Luca, Veronica Codullo, Elisa Visalli, Francesco Masini, Antonietta Gigante, Silvia Bellando-Randone, Greta Pellegrino, Erika Pigatto, Maria Grazia Lazzaroni, Franco Franceschini, Elena Generali, Gianna Mennillo, Simone Barsotti, Giuseppa Pagano Mariano, Francesca Calabrese, Federica Furini, Licia Vultaggio, Simone Parisi, Clara Lisa Peroni, Davide Rozza, Anna Zanetti, Greta Carrara, Giampiero Landolfi, Carlo Alberto Scirè, Gerolamo Bianchi, Enrico Fusaro, Gian Domenico Sebastiani, Marcello Govoni, Salvatore D'Angelo, Franco Cozzi, Andrea Doria, Florenzo Iannone, Carlo Salvarani, Marco Matucci-Cerinic Autoimmunity Reviews, 2022
Autophagy Hijacking in PBMC From COVID-19 Patients Results in Lymphopenia Cristiana Barbati, Alessandra Ida Celia, Tania Colasanti, Marta Vomero, Mariangela Speziali, Erisa Putro, Giorgia Buoncuore, Flavia Savino, Serena Colafrancesco, Federica Maria Ucci, Claudia Ciancarella, Eugenia Balbinot, Susanna Scarpa, Francesco Natalucci, Greta Pellegrino, Fulvia Ceccarelli, Francesca Romana Spinelli, Claudio Maria Mastroianni, Fabrizio Conti, Cristiano Alessandri Frontiers in Immunology, 2022
Sex-related Differences in Systemic Sclerosis: A Multicenter Cross-sectional Study From the National Registry of the Italian Society for Rheumatology Rossella De Angelis, Dilia Giuggioli, Gianluigi Bajocchi, Lorenzo Dagna, Giovanni Zanframundo, Rosario Foti, Fabio Cacciapaglia, Giovanna Cuomo, Alarico Ariani, Edoardo Rosato, Serena Guiducci, Francesco Girelli, Valeria Riccieri, Elisabetta Zanatta, Silvia Bosello, Ilaria Cavazzana, Francesca Ingegnoli, Maria De Santis, Giuseppe Murdaca, Giuseppina Abignano, Nicoletta Romeo, Alessandra Della Rossa, Maurizio Caminiti, Annamaria Iuliano, Giovanni Ciano, Lorenzo Beretta, Gianluca Bagnato, Ennio Lubrano, Ilenia De Andres, Alessandro Giollo, Marta Saracco, Cecilia Agnes, Federica Lumetti, Amelia Spinella, Luca Magnani, Corrado Campochiaro, Giacomo De Luca, Veronica Codullo, Elisa Visalli, Francesco Masini, Antonietta Gigante, Silvia Bellando-Randone, Greta Pellegrino, Erika Pigatto, Francesca Dall’Ara, Maria Grazia Lazzaroni, Elena Generali, Gianna Mennillo, Simone Barsotti, Giuseppa Pagano Mariano, Francesca Calabrese, Federica Furini, Licia Vultaggio, Simone Parisi, Clara Lisa Peroni, Anna Maria Risa, Davide Rozza, Anna Zanetti, Greta Carrara, Giampiero Landolfi, Carlo Alberto Scirè, Gerolamo Bianchi, Enrico Fusaro, Gian Domenico Sebastiani, Marcello Govoni, Salvatore D’Angelo, Franco Cozzi, Andrea Doria, Florenzo Iannone, Carlo Salvarani, Marco Matucci-Cerinic, Clodoveo Ferri, and Journal of Rheumatology, 2022
Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies Clodoveo Ferri, Vincenzo Raimondo, Laura Gragnani, Dilia Giuggioli, Lorenzo Dagna, Antonio Tavoni, Francesco Ursini, Massimo L'Andolina, Francesco Caso, Piero Ruscitti, Maurizio Caminiti, Rosario Foti, Valeria Riccieri, Serena Guiducci, Roberta Pellegrini, Elisabetta Zanatta, Giuseppe Varcasia, Domenico Olivo, Pietro Gigliotti, Giovanna Cuomo, Giuseppe Murdaca, Riccardo Cecchetti, Rossella De Angelis, Nicoletta Romeo, Francesca Ingegnoli, Franco Cozzi, Veronica Codullo, Ilaria Cavazzana, Michele Colaci, Giuseppina Abignano, Maria De Santis, Ennio Lubrano, Enrico Fusaro, Amelia Spinella, Federica Lumetti, Giacomo De Luca, Silvia Bellando-Randone, Elisa Visalli, Ylenia Dal Bosco, Giorgio Amato, Daiana Giannini, Silvia Bilia, Francesco Masini, Greta Pellegrino, Erika Pigatto, Elena Generali, Giuseppa Pagano Mariano, Giorgio Pettiti, Giovanni Zanframundo, Raffaele Brittelli, Vincenzo Aiello, Rodolfo Caminiti, Daniela Scorpiniti, Tommaso Ferrari, Corrado Campochiaro, Veronica Brusi, Micaela Fredi, Liala Moschetti, Fabio Cacciapaglia, Sabrina Rosaria Paparo, Francesca Ragusa, Valeria Mazzi, Giusy Elia, Silvia Martina Ferrari, Ilenia Di Cola, Marta Vadacca, Sebastiano Lorusso, Monica Monti, Serena Lorini, Maria Letizia Aprile, Marco Tasso, Mario Miccoli, Silvia Bosello, Salvatore D'Angelo, Andrea Doria, Franco Franceschini, Riccardo Meliconi, Marco Matucci-Cerinic, Florenzo Iannone, Roberto Giacomelli, Carlo Salvarani, Anna Linda Zignego, Poupak Fallahi, Alessandro Antonelli Current Pharmaceutical Design, 2022
Covid-19 and rheumatic autoimmune systemic diseases: Role of pre-existing lung involvement and ongoing treatments Clodoveo Ferri, Dilia Giuggioli, Vincenzo Raimondo, Massimo L’Andolina, Lorenzo Dagna, Antonio Tavoni, Francesco Caso, Francesco Ursini, Piero Ruscitti, Maurizio Caminiti, Rosario Foti, Valeria Riccieri, Serena Guiducci, Roberta Pellegrini, Elisabetta Zanatta, Giuseppe Varcasia, Domenico Olivo, Pietro Gigliotti, Giovanna Cuomo, Giuseppe Murdaca, Riccardo Cecchetti, Rossella De Angelis, Nicoletta Romeo, Francesca Ingegnoli, Franco Cozzi, Veronica Codullo, Ilaria Cavazzana, Michele Colaci, Giuseppina Abignano, Maria De Santis, Ennio Lubrano, Enrico Fusaro, Alessandra Della Rossa, Amelia Spinella, Federica Lumetti, Giacomo De Luca, Silvia Bellando-Randone, Elisa Visalli, Ylenia Dal Bosco, Giorgio Amato, Daiana Giannini, Silvia Bilia, Francesco Masini, Greta Pellegrino, Erika Pigatto, Elena Generali, Giuseppa Pagano Mariano, Giorgio Pettiti, Giovanni Zanframundo, Raffaele Brittelli, Vincenzo Aiello, Rodolfo Caminiti, Daniela Scorpiniti, Tommaso Ferrari, Corrado Campochiaro, Veronica Brusi, Micaela Fredi, Liala Moschetti, Fabio Cacciapaglia, Laura Gragnani, Monica Monti, Serena Lorini, Sabrina Rosaria Paparo, Francesca Ragusa, Valeria Mazzi, Giusy Elia, Silvia Martina Ferrari, Ilenia Di Cola, Marta Vadacca, Sebastiano Lorusso, Simone Barsotti, Maria Letizia Aprile, Tasso Marco, Mario Miccoli, Silvia Bosello, Marco Matucci-Cerinic, Salvatore D'Angelo, Andrea Doria, Franco Franceschini, Riccardo Meliconi, Florenzo Iannone, Roberto Giacomelli, Anna Linda Zignego, Poupak Fallahi, Alessandro Antonelli Current Pharmaceutical Design, 2021
Systemic sclerosis progression INvestiGation (SPRING) Italian registry: Demographic and clinico-serological features of the scleroderma spectrum Clinical and Experimental Rheumatology, 2020
